5-membered heteroarylcarboxamide compounds for the treatment of hbv
By disrupting the assembly of HBV core proteins using 5-membered heteroarylformamide compounds, this approach addresses the shortcomings of existing HBV treatments, provides a more effective means of viral suppression, and reduces the risk of drug resistance.
CN122167357APending Publication Date: 2026-06-09ASSEMBLY BIOSCIENCES INC
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ASSEMBLY BIOSCIENCES INC
- Filing Date
- 2021-04-21
- Publication Date
- 2026-06-09
AI Technical Summary
Technical Problem
Current HBV treatments mainly rely on nucleoside analogs and interferon-alpha. The former cannot eliminate the infection, while the latter has significant side effects and is only effective for some patients, resulting in a lack of effective treatments for HBV infection.
Method used
We provide 5-membered heteroarylformamide compounds and their pharmaceutical compositions for disrupting HBV core protein assembly and inhibiting viral replication.
Benefits of technology
This compound can effectively disrupt the assembly of HBV core proteins, potentially replacing existing treatment options, reducing viral replication, lowering the risk of viral resistance, and improving treatment efficacy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure FT_1 
Figure FT_2 
Figure SMS_19
Abstract
The present disclosure provides, in part, 5-membered heteroaryl formamide compounds useful for disrupting HBV core protein assembly and pharmaceutical compositions thereof and methods of treating hepatitis B (HBV) infection.
Need to check novelty before this filing date? Find Prior Art